Skip to main content
. Author manuscript; available in PMC: 2018 Oct 30.
Published in final edited form as: Am J Transplant. 2018 Aug 30;18(10):2483–2495. doi: 10.1111/ajt.15040

TABLE 3.

Cost‐related parameters for the Monte Carlo simulation evaluating the cost‐effectiveness of HCV (hepatitis C) treatment timing among kidney transplant Candidates

Cost element Costa Range Source
HCV
 F0 245 185–305 Davis (2011)20
 F1 245 185–305
 F2 245 185–305
 F3 440 315–550
 F4 830 620–1050
Waitlist 87 597 60 000–100 000 USRDS (2017)29
SVR 0.5 × HCV Davis (2011)20
Regimen 1
 (glecaprevir/
 pibrentasvir),
 4 weeks		 9830 8000–13 200 Federal Supply Schedule
 Price
Regimen 2
 (grazoprevir/
 elbasvir), 4 weeks		  15 840 10 920–17 377 Federal Supply Schedule
 Price, Truven Health
 Analytics
Toxicity event 241 120–360 Ferenci (2014)
 Chaiwat (2009)
 Gao (2012)49–51
Transplant, first year 130 545 100 000–180 000 USRDS (2017)29
Transplant, after
 first year		 24 282 15 000–40 000 USRDS (2017)29

SVR, sustained viral response.

a

USD, 2017.